PK
Prof. Karl Mann
Key Opinion Leader; Professor Emeritus at Central Institute of Mental Health, University of Heidelberg
Kinnov TherapeuticsTherapeutic Areas
Kinnov Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KT-110 | Alcohol Use Disorder (AUD) - Severe | Phase 3 |
| KT-110 (New Galenic Form) | Alcohol Use Disorder (AUD) | Formulation Testing |
Leadership Team at Kinnov Therapeutics
ED
Emmanuel de Rivoire
Managing Director
AP
Alain Puech
Medical Director
PH
Prof. Henri-Jean Aubin
Principal Investigator for Phase 2 trial; Professor of Psychiatry and Addictology at Hôpital Pitié-Salpêtrière
JG
Julien Guiraud
Co-author of Phase 2 publication; Vergio Consulting
PW
Prof. Wim van den Brink
Key Opinion Leader; Professor Emeritus of Psychiatry and Addiction at Academic Medical Center, University of Amsterdam
PA
Prof. Antoni Gual
Key Opinion Leader; Head of the Addictions Unit Neurosciences Institute at University of Barcelona
PR
Prof. Raymond Anton
Key Opinion Leader; Professor Emeritus of Psychiatry and Addictions at Medical University of South Carolina